My posts are my opinions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PMCM #1 MOMO PLAY! Could see .13 soon from .0122 cents. Expecting a nickel easy this week boys and girls.
PMCM #1 MOMO PLAY! Could see .13 soon from .0122 cents. Expecting a nickel easy this week boys and girls.
PMCM to da moon this week! Hitting Offer in the a.m. hard and they have a lot of news coming this week with their platinum artist dropping the single on Tuesday!
PMCM to da moon this week! Hitting Offer in the a.m. hard and they have a lot of news coming this week with their platinum artist dropping the single on Tuesday!
PMCM trading Millions of Dollars all Organic & Natural this is huge and far from an ihub play or pinky play. PMCM is going to nickel and dime land very soon just like NTEK did. Same people are loading here now.
PMCM trading Millions of Dollars all Organic & Natural this is huge and far from an ihub play or pinky play. PMCM is going to nickel and dime land very soon just like NTEK did. Same people are loading here now.
SEC.gov proof they did NOT name BIZM - SEC did NOT name BIZM and that is a fact. Here you go from the SEC.gov complaint on the SEC.gov website. I stand correct with the fatcs that the SEC did NOT name BIZM. No need to go any further with opinions as we have the FACTS from the Sec.gov website as show below!
The SEC’s complaint, filed in U.S. District Court in Manhattan, charges the eight defendants — Magdalena Tavella, Andres Horacio Ficicchia, Gonzalo Garcia Blaya, Lucia Mariana Hernando, Cecilia De Lorenzo, Adriana Rosa Bagattin, Daniela Patricia Goldman and Mariano Pablo Ferrari — along with two others, Mariano Graciarena and Fernando Loureyro, who received shares but have yet to sell them.
SEC Complaint
Biozoom, formerly Entertainment Art, Inc., announced in April that it was changing its name and moving from producing leather bags to developing biomedical technology. The SEC’s complaint alleges that from March to June 2013, the ten defendants received more than 20 million shares of Entertainment Art, which was one-third of the company’s total outstanding shares. In a one-month period beginning in mid-May, eight of them sold more than 14 million shares. The sales yielded almost $34 million, of which almost $17 million was wired to overseas bank accounts. Their U.S. brokerage accounts, which include approximately $16 million in cash, are subject to the asset freeze.
The SEC’s complaint, filed in U.S. District Court in Manhattan, charges the eight defendants — Magdalena Tavella, Andres Horacio Ficicchia, Gonzalo Garcia Blaya, Lucia Mariana Hernando, Cecilia De Lorenzo, Adriana Rosa Bagattin, Daniela Patricia Goldman and Mariano Pablo Ferrari — along with two others, Mariano Graciarena and Fernando Loureyro, who received shares but have yet to sell them.
“Today’s action, along with the SEC’s trading suspension order last week, demonstrate the SEC’s ability and commitment to act swiftly to halt ongoing illegal conduct and preserve assets,” said Antonia Chion, Associate Director in the SEC’s Division of Enforcement.
According to the SEC’s complaint, when the defendants deposited the Biozoom stock into their U.S. brokerage accounts, they claimed to have acquired the bulk of the shares in March 2013 from Entertainment Art shareholders who purchased them in private placements that began in 2007. Each of the defendants provided stock purchase agreements between them and the former shareholders purportedly signed by the defendants and those shareholders. The SEC alleges that the documents were false because the Entertainment Art investors had sold all of their stock in the company in 2009, almost four years earlier. The defendants’ shares of Biozoom were deposited into their accounts as shares that purportedly could be freely traded and the defendants sold them even though no registration statement was filed with the SEC for any of the sales transactions, in violation of U.S. law.
In addition to the temporary restraining order and asset freeze granted by the court, the SEC is seeking preliminary and permanent injunctions, return of the selling defendants’ allegedly ill-gotten sale proceeds, and civil penalties. The SEC also seeks preliminary and permanent injunctions against the non-selling defendants, Graciarena and Loureyro, because of the likelihood that both defendants will offer or sell their Biozoom shares to the public in violation of the registration requirements of U.S. securities law.
Ricky Sachar, Scott Lowry, Deborah Tarasevich, Jennie Krasner, and Robert Nesbitt conducted the SEC’s investigation, which is continuing. Patrick M. Bryan will lead the litigation. The SEC acknowledges the assistance of the Financial Industry Regulatory Authority (FINRA).
# # #
http://www.sec.gov/news/press/2013/2013-122.htm
BIZM_MASTER DD_Uplisting_Again_and _SEC_shows_BIZM_is_not_a_scam.
The company was formed in 2004 by German scientists and engineers, to explore and exploit cutting edge optics technologies that the founders had been researching and developing. In 2004, the optics development company established a joint venture called Opsolution Mobile (later renamed to Biozoom Services GmbH) with European telecom giant, Vodafone, to explore potential applications for their technologies in the area of remote telemedicine through cellular phone devices. In 2007, Opsolution Spectroscopic Systems GmbH was organized to facilitate an engineering and development partnership with another reputable entity, Carl Zeiss Microscopy GmbH, an international conglomerate and world leader in optical engineering. The Opsolution Nanophotonics GmbH success of miniaturizing traditional spectroscopic systems to nanoscopic scale lead in 2008, 2009 and 2010 to government grants for the founders to continue their R&D work.
The facts are the SEC halted BIZM stock for 10 days in order to conduct an investigation on Rule 144 stock that was being sold. SEC has filed its charges and did NOT name BIZM therefore it lifted the halt to let it trade again and go back to doing business. The SEC/Government only named and charged the 10 Argentinians for selling BIZM stock they should not of sold because it was Rule 144 stock so therefore BIZM (the company) is not guilty or at fault and was NEVER named by the SEC (this is Fact) !
SEC has proven the naysayers wrong because the Government aka the SEC did not name BIZM so its NOT a scam. SEC/Government only named the 8 Argentinians that had BIZM stock they should not of had and not of been allowed to clear it however the SEC aka Government did NOT name BIZM so BIZM is good to go and in the clear. People are entitled to their opinions but the SEC aka Government is right because they are the regulators here and they did NOT find BIZM to be a scam and therefore they did NOT name BIZM.
BIZM Short Term Trading Upside-Rebound-Bounce-Short Covering and more. Here is the short term outlook I have concluded after doing countless hours of research (see below). I personally feel BIZM will provide for some massive gains short term and long term once it get its S-1 or 15c211 approved.
BIZM Uplisting via S-1 and be fully reporting again: As I mentioned I felt the company had a trick up their sleeve in order to skip all the b/s with the normal filing of a 15c211. All they have to do is file a new S-1 to up-list and become fully reporting again. This is exactly why the company filed its 10K just 2 weeks ago so they would be fully reporting and would NOT lose that status they needed when filing their new S-1. BIZM is already fully reporting as far as filing is concerned so now all they need is to work with the SEC as they have stated they & their law firm are doing to get the S-1 approved again and therefore uplist again.
We already have proof in the 10K and now in an email from the company that they are working with the SEC and their counsel to get things back on track and resolved which means their S-1 approved. BIZM would run wild once they update the market on this and or get it approved.
BIZM recent solid news and links:
Biozoom Enters Into Commercial Phase of Scanner Production
Move from prototype to production environment is final step before mass scale production and commercial distribution http://finance.yahoo.com/news/biozoom-enters-commercial-phase-scanner-111300740.html
Biozoom's Advanced Nanospectroscopy Based On Licensable, Cutting-Edge Intellectual Property With Many Possible Applications. More than 15 international patents and pending patents comprise a potential revenue source and a powerful R&D resource for licensees http://finance.yahoo.com/news/biozooms-advanced-nanospectroscopy-based-licensable-131500283.html
Biozoom Releases Clinical Study By Charite University Hospital, Indicates Health Scanner Is Effective For Empowering Long-Term Healthier Lifestyle. Renowned university hospital's initial results report 20% of subjects quit smoking and 83% tested for higher levels of antioxidants http://finance.yahoo.com/news/university-researchers-biozoom-scanner-investigate-131500487.html
University Researchers Use Biozoom Scanner To Investigate Relationship Between Stress And Work. Study demonstrates Biozoom scanner's ability to help users measure and manage stress for improved physical and emotional wellbeing http://finance.yahoo.com/news/university-researchers-biozoom-scanner-investigate-131500487.html
Biozoom Exercises Purchase Option Under Joint Venture Agreement With Spectroscopic Technology Developer, Opsolution. Biozoom to fund Opsolution's continuing research and development, and is assigned rights to all current and future intellectual property http://finance.yahoo.com/news/biozoom-exercises-purchase-option-under-170400076.html
Dr. Jurgen Lademann Accepts Post As Chairman Of Biozoom's Scientific Advisory Board. Internationally renowned professor validated and led nine successful studies using Biozoom scanner, sees many consumer and professional applications of technology http://finance.yahoo.com/news/dr-jurgen-lademann-accepts-post-124500731.html
Bestselling Author, Chef And Wellness Celebrity, Attila Hildmann, To Use Biozoom Scanner In His New Fitness Challenge. 250 participants will follow Hildmann's Vegan Forever Young lifestyle recommendations for 60 days and measure the health benefits using Biozoom's handheld scanner http://finance.yahoo.com/news/bestselling-author-chef-wellness-celebrity-132500818.html
Biozoom Announces High-Profile Appointments To Scientific Advisory Board. Innovators, inventors and experts in dermatology, cosmetics and cancer research to guide evolution of the technology, applications and markets http://finance.yahoo.com/news/biozoom-announces-high-profile-appointments-134700696.html
Executive Leadership Team Brings Decades of Entrepreneurial, Manufacturing and Innovation Success to Biozoom. Co-founders Hardy Hoheisel and Wolfgang Koecher Named CEO and CTO http://finance.yahoo.com/news/executive-leadership-team-brings-decades-132500897.html
What is Biozoom?
The leading edge of healthcare technology
The Biozoom scanner is the result of more that eight years of investigation, innovation, engineering and collaboration. This remarkable handheld unit is used in concert with Biozoom’s equally sophisticated and medically validated analytical algorithms. At the press of a button, the scanner collects and sends spectroscopic data to Biozoom’s servers, which instantly returns biofeedback to the user.
The founders of Biozoom have been engaged in developing cutting edge optics since 2004. Over the past several years, the founders were involved in a variety of ventures, each dedicated to evolving the efficacy and practical use of optical scanners. Working with European telecom giant Vodafone, the founders developed an application for two-way remote telemedicine through cellular phone devices. In 2007, they undertook an engineering and development partnership with Carl Zeiss, which succeeded in miniaturizing the optical system considerably. After a period of grant-supported research and development, Biozoom's executive management established the company in 2013 to bring this extraordinary technology to the market.
- See more at: http://www.biozoom.net/about_us.php
Biozoom Executive Management - A proven leadership team:
Hardy Hoheisel, CEO
Hardy Hoheisel is a successful athlete, innovator and entrepreneur. After completing his education in micro- and macroeconomics, he worked in sports marketing. He founded his first company, which was dedicated to the development, production and marketing of sports equipment, in 1992. He discovered Kite Surfing in the U.S., a popular water sport today, and then positioned and marketed it in Europe using effective sports and event marketing techniques. After the sale of this company, and then winning a business competition, the ambitious triathlete founded Opsolution with the objective of generating an optical biofeedback system. Based on his scientific developments, he started a joint venture between Opsolution and Vodafone. From 2004 until 2009, he was a member of the supervisory board of a Vodafone company. He founded Biozoom with Dr. Wolfgang Köcher in 2013.
Wolfgang Köcher, CTO
Dr. Wolfgang Köcher received his PhD at the University of Kassel in 1986. In 1987, the university appointed him as a chief engineer for system design. In this role, he assumed leadership of development projects for combined home heating and power based on Stirling engines, Stirling air-condition systems and systems applying CO2 as a refrigerant. He won international attention for developing a new method for guiding R&D according to customer benefits and preferences. He was also a reviewer for DBU, one of Europe’s largest foundations for innovative and exemplary environmental projects. In addition, Köcher spent 20 years as a consultant for a Japanese automotive company’s R&D institute. After shifting his scientific work to optical applications, he co-founded Opsolution, applying reflection spectroscopy to the development and production of small handheld systems. He founded Biozoom with Hardy Hoheisel in 2013.
Tefa Dexter
Tefa Dexter, Director of Business Development and Sales
Mr. Dexter has oversight of several mission-critical product development, business development and sales functions within the company. He has more than a decade of experience in brand development, strategic sales, product management, and social media driven customer loyalty. He brings with him strong relationships in the action sports, fashion and entertainment industries. Prior to joining Biozoom, Mr. Dexter co-founded of The Santa Barbara Group LLC, a technology company focused on developing interactive customer acquisition, marketing and loyalty sales. At the Santa Barbara Group, he led teams of developers in creating white-label B2B web and mobile products. He was principally responsible for developing unique web based technology portals for the action sports industry, with key clients including Billabong, Volcom and the Ultimate Fighting Championship.
Biozoom Scientific Board - Leading minds in technology and innovation
Prof. Dr. Lademann
Prof. Lademann is one of the leading experts on non-invasive measurement of biomarkers in human skin. He is head of the Center of Experimental and Applied Cutaneous Physiology at the Department of Dermatology, Venerology and Allergology of Charité Berlin. Charité Berlin is one of the largest hospitals in Europe, home to more than half of German Nobel Prize winners. He is editor of the international journal “Skin Pharmacology and Applied Skin Physiology,” and a member of the editorial board of the journals “Laser Physics Letters,” “Cosmetic Dermatology” and the “Journal of Biomedical Optics.” Dr. Lademann is also the President of the “International Society of Skin Pharmacology and Physiology” and Member of the Experts Team for Risk Assessment of Nanoparticles in Cosmetic Products with ECETOC AISBL, Brussels.
Prof. Lademann applied and tested the Biozoom scanner over more than 5 years, first in studies and now clinically.
Prof. Dr. Rudolph W. Kessler
Dr. Kessler is a Professor of Chemistry at Reutlingen University, where he also heads the Process Analysis Group at the Reutlingen Research Institute. After his studies in Chemistry and a PhD in Physical Chemistry at the University of Tübingen and in Norwich/UK, he worked for many years with Mercedes Benz at the Basic Research Department in Stuttgart. His main research areas are in optical and spectroscopic process analysis methods in combination with multivariate data analysis. Another focus is on chemical imaging and near field spectroscopy. He has implemented several online systems for industry over the past 20 years and also works as a consultant for knowledge based manufacturing. He was nominated in 2009 for the President of the German Republic’s Future Prize, and he won the Research Prize of Reutlingen University in 2009.
Prof. Dr. Leonhard Zastrow
Dr. Zastrow holds 99 patents and has authored more than 100 scientific articles. He is a consulting scientist with the Center of Experimental and Applied Cutaneous Physiology at Charité Berlin. For more than 20 years, Dr. Zastrow held research positions in the cosmetics industry. He was Senior Vice President of Research and Development for international cosmetics giant, Coty Inc., from 1993-2011. Prior to his work in industry, he headed the Institute for Fatty Chemistry at the German Academy of Sciences’ Central Institute for Organic Chemistry. His areas of research include radiation and the interaction of radiation with biological systems as well as the development of protective and neutralizing systems against free radicals in biological systems.
Prof. Dr. Hasan Mukhtar
Dr. Mukhtar is Professor of Cancer Research and Director and Vice Chair of the Research Department of Dermatology University of Wisconsin Medical Science Center. Prof. Mukhtar is a leading scientist in the development of novel, mechanism-based dietary agents for prevention and treatment of skin diseases and cancer. The Mukhtar laboratory was the first to establish the potential role of green tea polyphenols for prevention of skin (both chemical and photo-carcinogenesis models), lung and prostate cancers. It was also the first to define potential cancer chemopreventive effects of a wide variety of dietary agents.The Mukhtar laboratory has expertise in molecular and cellular biology, biomarker assessment and considerable experience with the use of various animal tumor bioassays of induced and transgenic models. Prof. Mukhtar is member of editorial board and associated editor of 38 scientific magazines and has published more than 500 papers. - See more at: http://www.biozoom.net/about_us.php
Biozoom Demonstrated Benefits
Proven accurate and effective, Biozoom is a critical component in managing a user's antioxidant levels, nutritional uptake and overall fitness. We combine handheld reflection spectroscopy with instant online analysis, expert nutritional advice and active wellness coaching to support your good health.
Health and Wellness
The data and support you need
When it comes to supporting your health, knowledge is power. The Biozoom is a state of the art, non-invasive, preventative biofeedback system that can be used anywhere and anytime. Users get real-time analysis of several key biomarkers, including nutritional uptake—or how well your body is metabolizing your diet. At the Biozoom portal, your results are instantly analyzed and used to build a personal action plan for improving your health and wellbeing.
Biozoom also enables users to actively manage antioxidant levels. Antioxidants are substances the body uses to defend against a whole range of health worries. By preventing the emergence of free radicals, antioxidants keep you feeling and looking more youthful. Antioxidants also help to protect you against diseases and the detrimental aging effects of smoking, alcohol, dietary choices, sleep deprivation, and the ravages of stress. With Biozoom, you can know if you are getting sufficient antioxidants in your diet.
Best of all, you'll receive expert coaching from Biozoom—based on your specific needs—to help you achieve a healthy physiological balance. - See more at: http://www.biozoom.net/benefits.php
Biozoom Clinical Validation - Laboratory-quality results:
Before a new health-related technology enters the market, it must be clinically proven. This is especially so with the Biozoom scanner, which is the world’s first spectroscopic device designed for use by the public in for detecting important health biomarkers. Our scanner readings become the basis for personalized, medically validated biofeedback you can use to make positive lifestyle changes. For clinical validation, we took Biozoom to unbiased experts.
Charité Berlin is one of the biggest hospitals in Europe. A major university hospital in Germany, Charité is home to nearly half of German’s Nobel Prize recipients. Charité was the site of a study testing the Biozoom scanner against the hospital’s existing Raman spectroscopy device. The Raman device is used routinely to conduct a variety of analyses. It is a well-established method for determining antioxidant levels as well. The Biozoom scanner was used on the left and right palms of 30 adult volunteers and compared against the hospital’s spectrometer. The study’s findings, which were published in the July 2012 issue of the Journal of Biophotonics showed Biozoom to be as effective as the hospital’s spectrometer view it at http://onlinelibrary.wiley.com/doi/10.1002/jbio.201100080/abstract.
"Biozoom provides our physicians with rapid, accurate and validated feedback about important biomarkers. We have used Biozoom for three years, and we consider it an essential device for daily health maintenance"
[img]Prof. Dr. Juergen Lademann
Head of Department of Skin Physiology
Charité Berlin Germany[/img]
With Biozoom, you too can have the benefits of laboratory-quality diagnostics in an affordable, handheld, easy to use scanner.
- See more at: http://www.biozoom.net/benefits.php
Biozoom in Action - Causing change for the better:
With the Biozoom scanner proven to yield results as accurate as hospital spectrometers, we commissioned another study with Charité Berlin. For this study, 50 students participated. The question was: Would using the Biozoom scanner lead "healthy" people to make behavioral changes in diet, smoking, alcohol consumption and other actions that negatively affect antioxidant levels?
Each student self-scanned to measure baseline antioxidant levels, and then scanned again at regular intervals to chart any changes. All students were provided a nutritious, well-balanced lunch, and were also presented with lifestyle coaching and suggestions to improve their wellness. The results were phenomenal: Once the students were able to measure the deficiencies in their biomarkers, a full 80% worked to create improvements in key antioxidants. Many reported eating better and drinking less alcohol. In addition, 20% of the students were motivated to quit smoking.
Biozoom is now used clinically at Charité Berlin, determining patients' tissue perfusion and antioxidant status. - See more at: http://www.biozoom.net/benefits.php
Biozoom Technology - Biozoom's scientific team has created the world's only portable, handheld device that anyone can use to measure biomarkers in the human body. This cutting edge, clinically validated technology makes real-time biofeedback a driving force in the multi-billion dollar health and wellness industry.
Biozoom designs, develops and manufactures innovative handheld devices that make the widespread commercial use of spectroscopy possible. Built on more than 18 international patents and pending patents, the first consumer application of Biozoom technology focuses on the multi-billion dollar health and wellness industry. Using cutting edge measuring and medical modeling techniques, Biozoom's transdermal scanner measures key biomarkers, giving users the information they need to take control of their wellbeing. - See more at: http://www.biozoom.net/technology.php
Biozoom How it Works - Handheld mobile spectroscopy:
Because various biomarkers reflect light differently, their presence can be detected with the right technology. The Biozoom scanner detects biomarkers by radiating light into the skin of the user’s palm using LED, and guiding the back reflected light to a spectroscopic system developed in partnership with Carl Zeiss. The data are sent to Biozoom’s servers, where they are run through a proprietary and medically validated algorithm. This entire process takes roughly 16 milliseconds, after which the results are sent directly to the user’s account on the Biozoom portal.
The Biozoom device is currently calibrated to measure:
Antioxidant levels VO2 max
Cytochrome c-Oxidase Skin moisture
Stress levels
Biozoom Discovery & Development - Breakthrough technological achievement:
Traditionally, human biomarkers are measured using blood tests. Because the blood must be drawn and blood samples sent to a lab for analysis, relying on this method for biofeedback is slow and expensive.
Biozoom uses spectroscopy to measure biomarkers. Spectroscopy is a widely trusted technology, relying on the Beers-Lambert Law, which describes the way light is absorbed by compounds. Until now, the use of this technology was generally limited to laboratory analyses. Spectrometers are typically immobile, expensive and can only be used by professionals trained in its operation.
Building on several years of research and development processes—that include European cell phone giant Vodafone and world leader in optical engineering, Carl Zeiss—Biozoom's scientific team has created the world's only portable, handheld device that everyone can use to measure biomarkers in the human body.
Biozoom Nanospectroscopy - Bringing innovation to wellness:
Spectroscopy is a key technology in the medical, chemical and biophysical sciences, used to determine the concentration of substances in matter. Biozoom's breakthrough is in spectroscopy's practical miniaturization, which created a new kind of device, the Nanospectrometer.
Biozoom used its patents on Fabry-Pérot Filters to overcome the challenges of miniaturization necessary to create a successful Nanospectrometer. It is similar to the technology digital cameras use to capture images, but instead of only 3 color filters, Biozoom uses 256, capturing remarkably fine detail in a 1 mm by 1 mm area. The precise detection of complex substances is possible by multiplying this cluster spatial resolution. With the Nanospectrometer, Biozoom is enabling the next generation of spectroscopic readings, which will fit the technology into smartphones, tablets, music players, wrist watches and more. Biozoom puts the benefits of spectroscopy in a handheld device, affordable to anyone.
- See more at: http://www.biozoom.net/technology.php
Biozoom Future Developments - Applications in healthcare and beyond:
The near-term applications of Biozoom's scanner in medicine and healthcare could lead a long-awaited paradigm shift in healthcare: toward telemedicine. The missing element in telemedicine has always been the lack of a two-way flow of education, training, and health data. Now, a patient will be able to monitor and report findings from anywhere. In future versions of the scanner, Biozoom's non-invasive technology will enable the remote maintenance and monitoring of drug administration as well as numerous other physiological evaluators, including:
Cholesterol
Blood sugar
Blood alcohol
Drug screening
Over and above medicine, Biozoom's technology will be adapted to the needs of:
Government — including food safety, boarders patrols and homeland security forces
Pollution control — optimization of motor combustion and exhaust gas for real time
emission control and fuel efficiency
Insurance companies — population health and wellness monitoring
Local law enforcement agencies — field sobriety testing
- See more at: http://www.biozoom.net/technology.php
Biozoom Intellectual property - Fueling next-generation advancements:
Biozoom technology has multiple applications that could expand into numerous verticals. In the process of developing our scanner, we have also developed a portfolio of patented and patent-pending assets - more than 18 worldwide in areas as diverse as optics, temperature drift, data base management, spectroscopy, fuel consumption, fitness enzymes and more. Biozoom's optical work alone has a myriad of potential applications. Together, they comprise intellectual property assets that hold the key to new breakthroughs from Biozoom or from other technology companies with great ideas.
We recognize that the possibilities for innovation are limitless and welcome the opportunity to partner with or license technology to non-competing companies. - See more at: http://www.biozoom.net/technology.php
Short term upside:
BIZM opened for trading again on July 10, 2013. Most all knew BIZM would drop about 90% because of BIZM getting put on the greys from being halted for 10 days. This is just what happens when a company falls to the greys because their quoted security doesn't trade for 10 days but this now creates an opportunity for those out there to take advantage of BIZM while its trading off its lows and this is likely to mark the new bottom. From that bottom BIZM should run up multiples and rebound pretty high from that new bottom. Many are expecting it to bounce and run multi-times from the bottom short term. BIZM just filed its 10k and disclosed it has no legal proceedings (see bottom) and it was not named by the SEC.
Plus they have a major Intellectual Property Portfolio. BIZM has been doing solid business in Germany for roughly 9 years (since 2004) and is far from b/s (see below proof and in there filings for key things such as "In 2004, the optics development company established a joint venture called Opsolution Mobile (later renamed to Biozoom Services GmbH) with European telecom giant, Vodafone, to explore potential applications for their technologies in the area of remote telemedicine through cellular phone devices. ".
BIZM was trading $20 Million to $40 Million per day and marketed worldwide so tens of thousands of traders/investors watching it:
BIZM was marketed in news, media, print (newspapers), internet (web) and you name it. BIZM was one of the best when it comes to marketing and getting the word out there to the masses of traders/investors because it had huge numbers, audience and marketing that was done to it. BIZM has much better odds of rebounding higher and much stronger compared to all other greys. It comes down to numbers and numbers don't lie.
BIZM has the most eyes on it and when it rebounds it will likely rebound big because BIZM was marketed like gorilla warfare. BIZM was trading $20 million to $40 million per day. BIZM will be a multi-home run this month from July 10th imo and the best news is the company was NOT named today in the SEC filing.
Shorts and Short covering:
There are likely millions upon millions of shares shorted on BIZM right now. One thing for sure is that this is wrong "Short interest reported on OTCBB is complete false. It is impossible to know what the true short is from merely looking online. Many shares are shorted naked, broker to broker or ex-clearing. Most shorts don't show up nor will they ever show up unless BIZM pulls the NOBO (non objective beneficial owners) and DTC. That is the ONLY true way to know what the true short is here. Also its not about interactive brokers, sure trade, etc allowing shorts. If a large investor or institutional investor has a prime brokerage account with the right capital in it, they could of easily shorted tons of BIZM shares.
I'm glad there are millions shorted in BIZM because it will likely work in the longs favor short term. Shorts are traders and just like everyone else, they like to make money. So when BIZM gaps down on July 10th there will be many of them trying to cover which means buying BIZM shares and as it rebounds and starts to trade up it will force more covering & buying short term imo.
BIZM just filed its 10K and is being fully transparent:
I am feeling pretty positive right about now knowing the company has filed all this and is working to turn this 800 pound gorilla back around.. Yes the stock is taking a hit but it looks like its going to make a come back.
Plus BIZM has a major Intellectual Property Portfolio. This company has been doing solid business in Germany for roughly 9 years (since 2004) and is far from b/s (see below proof and in there filings for key things such as "In 2004, the optics development company established a joint venture called Opsolution Mobile (later renamed to Biozoom Services GmbH) with European telecom giant, Vodafone, to explore potential applications for their technologies in the area of remote telemedicine through cellular phone devices. ".
10-K/A http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9384999
10-K http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9384582
About the Opsolution Entities and Business
History
The Opsolution Entities trace their origins to an optics development concern formed in 2004 by German scientists and engineers, to explore and exploit cutting edge optics technologies that the founders had been researching and developing. In 2004, the optics development company established a joint venture called Opsolution Mobile (later renamed to Biozoom Services GmbH) with European telecom giant, Vodafone, to explore potential applications for their technologies in the area of remote telemedicine through cellular phone devices. In 2007, Opsolution Spectroscopic Systems GmbH was organized to facilitate an engineering and development partnership with another reputable entity, Carl Zeiss Microscopy GmbH, an international conglomerate and world leader in optical engineering. The Opsolution Nanophotonics GmbH success of miniaturizing traditional spectroscopic systems to nanoscopic scale lead in 2008, 2009 and 2010 to government grants for the founders to continue their R&D work.
Some of the intellectual property we have acquired is still subject to joint venture rights of Vodafone or its successor in interest and assignees or Carl Zeiss and their assignees, as provided below.
The patents purchased are primarily for use in spectroscopy. A complete list of these patents is listed below.
Initial Device; Technologies and Focus; Spectroscopy and Two-Way Diagnostic Communication
The Company’s objective is to further develop, and commercialize through license or marketing, a mobile platform for remote collection of biomedical data. This involves an important technology known as “spectroscopy.” Spectroscopy is the interaction between matter, specifically cells, and radiated energy. Spectroscopy technology is vital to determining concentrations of certain substances in medical, chemical and biological applications.
The initial patents and intellectual property purchased in the Opsolution Acquisition relates to the development and patent of small handheld devices that utilize reflection spectroscopy and optical feedback, to determine a person’s health and wellbeing. A common example of spectroscopy used in medicine is a basic pulse oximeter in use and existence today. A pulse oximeter is a small device externally attached to a finger which utilizes light refraction to instantly provide a blood oxygen concentration in the blood, without use of needles or other invasive techniques. Our technology, however, is being utilized to determine far more than simply oxygen content.
Biofeedback is an effective means for an individual to learn how to influence physiological activity, for purposes of diagnosing nutritional and other health problems.
Our Biofeedback device is designed to be a small, simple, mobile and inexpensive mechanism that collects biological data from individuals to detect antioxidants and nutritional and other health markers. This device is designed to avoid complex, messy and timely blood tests. Because it is electronic, it can also be used remotely, such as in the home or at a clinic with results transferred by telemetry (phone, computer, etc.).
Current Calibration Applications
Currently the device is calibrated to measure carotenoids in human skin as a marker substance for the complete antioxidant network including vitamins, enzymes and other substances like flavonoids, lipoic acid, etc., allowing the calculation of stress due to the ascent or descant of the marker. Since a correlation was found between the spectroscopic measurement of Cytochrome C Oxidase and VO 2 max, the device can be used to determine the cardiorespiratory fitness of users.
Our devices will be calibrated, in several development steps, to detect and calculate the following:
· Antioxidant levels
· Vitamin levels
· Skin moisture (pre-mature aging)
· Oxidative stress
· Cytochrome C Oxidase
· VO 2 max (for endurance analysis)
In the future, we are hoping to be able to develop technologies that enable detection and measurement of cholesterol, blood sugar levels, alcohol, drugs, smoke poisoning, and even blood pressure.
No assurance can be made that we will be able to develop further applications, or, if we do, that we will be able to commercialize them.
Joint Venture Development of Our Technologies
Some of our intellectual property has been developed in partnership with other entities, namely Vodafone and Carl Zeiss Microscopy GmbH, a major engineering firm in Europe. Specifically, Carl Zeiss has assisted with production and design of the spectroscopic unit, and its calibration. Their assistance has allowed us to put the device to use in Charité Berlin, a top-tier and respected University Hospital in Europe.
Description of Shared Intellectual Property Terms
Some of our intellectual property was developed in conjunction with Vodafone’s subsidiary (Biozoom Services GmbH) and, subsequent to their liquidation, remains subject to a shared license. Certain other intellectual property we have was developed or acquired in partnership with Carl Zeiss Microscopy GmbH. To the extent that the intellectual property we acquired from the Opsolution Sellers was subject to the limitations of these agreements, we will be subject to them as well.
Vodafone Joint Ventured Intellectual Property
Pursuant to the terms of the liquidation of Vodafone’s related entities in November of 2006, Opsolution Spectroscopic Systems GmbH (“OSS”) entered into a liquidation agreement with Vodafone Ventures Ltd. and its related entities, as well as Biozoom Services GmbH; and subsequently, on January 7 th of 2009, these entities or their successors entered into an Agreement on Intellectual Property and Property Rights among themselves. This arrangement provided, among other things, for intellectual property owned by the Vodafone-related entities to inure to the benefit of its successor and a new, post-liquidation entity known as Vodafone Ventures Ltd. and OSS. The relevant terms of the Vodafone arrangements provided that, with respect to all intellectual property coming from this transaction:
· Basic technology and basic analysis software IP rights were assigned to Vodafone Ventures Limited and OSS.
· Jointly developed intellectual property, such as joint patent applications or jointly developed or filed patent applications, patents, trademarks, and other IP (the “ New Vodafone IP ” ) are divided among Vodafone and OSS (with OSS receiving, generally, between 45% and 67% of the royalty rights, depending on the intellectual property),
· Either Vodafone or OSS or its successors may use the New Vodafone IP rights for the central application of services for their own respective business operation without paying royalties to one another,
· OSS may use, on a royalty-free basis, New Vodafone IP rights for any other de-central application of services when the spectral analysis is analyzed locally on an electrical device connected to a scanner and telecom network, and either Vodafone or OSS may grant simple sublicenses for the New Vodafone IP rights, with royalty split on a pro-rata basis (i.e. currently 65% Vodafone and 35% Biozoom as successor). Development results can be used by Vodafone or OSS on a non-exclusive, unrestricted, irrevocable and royalty free basis, and
· We may be required to pay our pro-rata share of patent prosecution or defense costs.
Carl Zeiss Microscopy GmbH, and Other Joint Ventured Intellectual Property
Some of our intellectual property was acquired from, or as a result of joint efforts with, Carl Zeiss Microscopy GmbH, which resulted in a 50%-50% relationship on receipt of all royalties, or other developers.
Management believes that its relationship with Carl Zeiss Microscopy GmbH is of significant value to the Company. The Opsolution Sellers and their principals have developed their relationship with Carl Zeiss, a well-known high-end producer of optical systems, for over 10 years. They were also instrumental in securing the Charité, the medical university and hospital, as a valuable development partner of the Company’s devices.
The Company’s management and oversight / coaching portal will be conducted from the U.S. By using the German medical network and combined with designated U.S. scientists in all relevant faculties, management believes that the development of the data-based coaching system will be realized.
University of Kassel Research
We also own certain intellectual property and patents as a result of the relationship and license agreements between Opsolution GmbH and the University of Kassel. The university conducted certain research and implemented patent filing, as indicated in the chart below, and transferred the same to Opsolution Sellers for a purchase price of EUR 39,000 (plus VAT), EUR 5,000 per year, commencing the first year of market entrance of the sensor utilizing this technology, and a 2% royalty on sales.
Business Strategy
One of the company’s products is already in trial use in Europe. In order to successfully commercialize our intellectual property, management believes that further development and perfection of our devices, as well as developing relationships in our initial target markets, will both be necessary in order to create brand awareness and penetrate these markets. Specifically, management believes, that the next steps for the company are:
Optimization of existing software and hardware to maintain the high quality of the Biozoom(TM) scanner as the company’s serial product,
Realization of the Biozoom(TM) portal with a customer-oriented design,
Development of business-related databases to realize, among other things, central analysis of measurements, saving of results or comparing individual measurements with group results, etc.,
Continuation of research and medical studies to validate, for all skin types, the algorithm for analysing measurement with the serial product,
Starting cooperation with specialists in US for conducting a study with students to check and improve their behaviour concerning nutrition, smoking and alcohol consumption,
Filing / acquisition of further IP rights concerning the second generation of the Biozoom(TM) scanner, and
Licensing other of Biozoom’s IP to other technology development companies with the ability to develop and market the IP in fields other than health care and education.
Market Opportunity
The company believes that the initial and most readily viable markets will be the health care sector and education sector. Health care is constantly seeking more economical and less invasive ways to detect disease or deficiencies and to increase patient education as well as patient responsibility. With rising medical costs and decreasing coverage, the market for preventative diagnostics has been growing significantly.
Some target market applications include fitness and wellness, which will entail development of relationships with nutritional and pharmaceutical retail chains, as well as gyms. In addition, we believe that dieting companies and similar businesses would have an interest in our products.
The Company believes that the next logical step would be towards penetration of the healthcare industry, specifically, physicians and other healthcare professionals. Penetration of the healthcare industry, however, may entail certain government regulations with respect to certain applications and the claims we make for those applications. As the devices we produce will be designed to provide prompt and non-invasive diagnostic information, we believe that our product will achieve market acceptance quickly. In addition, our devices can be used for sports medicine.
Other viable applications of our products include law enforcement (including sports doping enforcement, alcohol or other substance abuse enforcement) and auto emissions management as well as other environmental applications.
We will require substantial additional capital in order to further develop our product to work properly and viably and to enter these markets efficiently. We will likely be required to enter into one or more sub-licensing, joint venture or distribution agreements with re-sellers of our products that may further erode our profit margins. No assurance can be made that we will complete development of these products, or, if we do and even if we enter the markets, that we will be profitable therein.
Intellectual Property Portfolio
As mentioned above, our intellectual property focuses on the spectroscopic technologies and bio-feedback to create a non-invasive, external scanning device that is able to scan and detect substances. All of the below technologies were acquired by our Biozoom subsidiary from the Opsolution Sellers in the Acquisition. Some of these patents are subject to joint venture or partnership agreements with other entities, namely, Vodafone or Carl Zeiss or their assigns. In addition to the below, we are also the beneficiaries of any other technologies developed or acquired by Opsolution GmbH, as a result of our Opsolution JV Agreement with them.
Jurisdiction and Patent Number
Date of filing
Name
% Owned
Status
Year of Expiration
DE 10 2006 003 499
January 24, 2006
Endurance/Fitness Determination of VO2 Max by measuring Cytochrome C Oxidase
45%(1)
Pending
DE 10 2005 063 263
December 30, 2005
Mathematical Model to compensate the temperature drift of LED when applying LED in spectroscopic devices
67.5%(1)
Pending
DE 10 2007 011 413
March 8, 2007
Transfer of data to central server for analyzing and checking plausibility of measurements before transferring or analyzing data
67.5%(1)
Pending
WO 2007/085435
January 24, 2007
Transfer of data to central server for analyzing and checking plausibility of measurements before transferring or analyzing data
45%(1)
Basis for national filing
International stage has ended
EP 1981398
January 24, 2007
Transfer of data to central server for analyzing and checking plausibility of measurements before transferring or analyzing data
45%(1)
Pending
WO 2007/077208
January 2, 2007
Mathematical model to compensate the temperature drift of LED in spectroscopic devices
67.5%(1)
Basis for national filing
International stage has ended
EP 2010890
January 2, 2007
Mathematical model to compensate the temperature drift of LED in spectroscopic devices
67.5%(1)
Pending
DE 10 2006 062 826
April 19, 2006
Mathematical model to compensate the temperature drift of LED in spectroscopic devices
100%
Pending
DE 10 2012 005 583
March 20, 2012
Optical unit of Biozoom scanner and databases for generating coaching information for customers on central server due to measurement results with Biozoom scanner
100%
Pending
WO 2013/023637
July 31, 2012
Optical unit of Biozoom scanner and databases for generating coaching information for customers on central server due to measurement results with Biozoom scanner
100%
Pending
Basis for national filing
International stage ends 2014
DE 10 2006 039 073
August 9, 2006
Arrangement of Fabry Pérot Filters on a filter array
100%
Pending
WO 2008/017490
August 9, 2007
Production of Nanospectrometer by applying nanoimprint and arrangement of Fabry Pérot Filters
100%
Basis for national filing
International stage has ended
EP 2057446
May 13, 2009
Production of Nanospectrometer by applying Nanoimprint and Arrangement of Fabry Pérot Filters on a filter array.
100%
Pending
US 2011/0043823
August 9, 2007
Production of Nanospectrometer by applying Nanoimprint and Arrangement of Fabry Pérot Filters on a filter array
100%
Pending
CN 101627289
Jan 13, 2010
Production of Nanospectrometer by applying Nanoimprint and Arrangement of Fabry Pérot Filters on a filter array
100%
Pending
DE 10 2009 037 706
August 17, 2009
Methode for the spectroscopic measurement of NO2 in the exhaust emission of cars
100%
Pending
DE 10 2006 012 681
March 20, 2006
Transfer of spectroscopic data to a central server and use of the results
100%
Pending
DE 11 2007 000 950
April 19, 2007
Mathematical model to compensate the temperature drift of LED when applying LED in spectroscopic devices
100%
Pending
DE 10 2006 039 071
August 9, 2006
Nanospectrometer Production of Fabry Perot filter array by applying nanoimprint
100%(3)
Granted April 19, 2012
DE 10 2005 024 271
May 27, 2005
Grating spectrometer used in present Biozoom scanner
50%(2)
Pending
US 7.692.790
May 10, 2006
Grating spectrometer used in present Biozoom scanner
50%(2)
Granted April 6, 2010
(1) Indicates ownership in a partnership or joint venture with Vodafone Ventures Limited, as legal successor to Biozoom Services GmbH, with between 45% and 67% interest to the Company as indicated, for certain applications. Each party may grant simple sublicense to third parties with royalties earned being shared in accordance with foregoing percentage. Parties must also share costs and expenses, enforcement costs, and patent filing/prosecution costs in accordance with such percentages.
(2) Indicates ownership in a partnership with Carl Zeiss Microscopy GmbH, with 50% interest to the Company as indicated, for certain applications. Royalties earned are to be shared in accordance with foregoing percentage. Parties must also share costs and expenses, enforcement costs, and patent filing/prosecution costs in accordance with such percentages.
(3) Indicates patents filed by the University of Kassal, which transferred the rights to Opsolution GmbH for aggregate cost of $39,000 (plus VAT), plus EUR 5,000 per year commencing the first year of market entrance with a sensor utilizing their technology. The University of Kassel also retains a 2% royalty on new products brought to market utilizing this sensor technology.
New Joint Venture Agreement with Opsolution GmbH
One of the Opsolution Sellers, Opsolution GmbH, anticipates receiving a German government grant to continue certain research. In order to facilitate this grant and further research, the results of which would inure to our benefit, our Biozoom subsidiary entered into the Opsolution JV Agreement with Opsolution GmbH expiring December 31, 2017.
The Opsolution JV Agreement provided, among other things, for retention by Biozoom of Opsolution for purposes of:
·continuing research and development on our behalf,
· filing, and perfecting from time to time, patents, trademarks and other rights, and
· irrevocably assigning rights to technologies and research that it develops.
In exchange therefore, and subject to certain other restrictions, Biozoom agreed to provide funding of up to $500,000 for the development of new prototypes on our behalf, said funds to be paid as follows:
· $100,000 which was due upon execution of the Opsolution JV Agreement, and
· $50,000 per month thereafter for 8 months.
Biozoom also acquired the right to a percentage of Opsolution for $500.00 per percentage point, which option it partially exercised on June 14, 2013, acquiring 19.9% of Opsolution for $9,950.
Among other conditions to continued funding, Opsolution is required to keep in good standing and continue to fulfill the requirements under a government grant commitment to Opsolution of no less than EUR 300,000 for development of the second-generation prototype scanner device for measuring antioxidants and other biomarkers. In addition, Opsolution shall reimburse Biozoom for services rendered from time to time.
The foregoing is a summary of the Opsolution JV Agreement and is qualified in its entirety by reference to the provisions of Exhibit 10.5 to this Report, which is incorporated by reference herein.
Industry and Competition
While we believe that our spectroscopic technologies are cutting edge and disruptive, we do compete against other larger companies with significantly greater resources, market reputation and acceptance and relationships than we have. Our goals are to be able to compete in terms of cost, accuracy, ease of use and portability.
Below is a non-exhaustive list of some competing companies that have conducted research in our business technologies, or that have explored our space, some of which are more advanced than us. We believe that many of these competitors’ products suffer from drawbacks of some kind or another, and that our product may be able to compete on the basis shown:
Euromedic’s Free Oxygen Radical Monitor (FORM): More expensive and requires trained personnel to use.
Pharmanex’s Raman Spectroscop e: Expensive, complex in nature, making it impractical for individual use
Mevitec : manufactures a product for metabolism analysis. It sells a metabolism screening system that non-invasively measures the redox potential on the palm. However, current unit cost exceeds $20,000.
VicMedic : Systems produces a device for the screening of such metrics as Muscle-to-Fat Ratios etc. The product is costly, and inaccurate.
Tanita : manufactures a skin-analysis unit, but it is very limited in scope, testing only moistness, sebum and fat levels.
Other competitors that have developed or explored technologies in this space include Cygnus, IBM, and others.
Employees
We currently have three full-time employees situated in Germany and two part-time employees in the US. None of these employees are covered by a collective bargaining agreement, and we believe our relationship with our employees is good. We also engage consultants on an as-needed basis to supplement existing staff.
Government Regulation
We are a research and development business and to date, have not commercialized or sold any products using our technologies in the US. Therefore, the Company cannot be certain exactly which governmental regulations will ultimately be applicable to the final products. However, certain of our products and manufacturing processes will be subject to regulation under various portions of the U.S. Federal Food, Drug and Cosmetic Act, if we consider expanding our applications for use in or as part of certain medical devices or diagnostic devices. The effects of this are that, among other things, our manufacturing facilities, when and if created, may be subject to delays on approval, and periodic inspection by the U.S. Food and Drug Administration, or FDA, other product-oriented federal agencies and various state and local authorities in the U.S. for compliance with the requirements of the FDA’s Quality System Regulation (formerly known as Good Manufacturing Practices), other federal, state and local regulations and other quality standards such as ISO 9001 or ISO 13485.
To the extent our products are used in medical devices or other regulated applications, our products may be subject to extensive medical, FDA or other government regulation, testing and pre-market approval or clearance processes. Prior to application for approval or clearance, we may need to conduct clinical trials to test the safety and efficacy of our products or we may be required to identify predicate devices to which we can establish substantial equivalence. In addition, we may be required to satisfy testing criterion or submit product applications in other countries where we intend to market our goods. These processes may take an extensive period of time and would necessarily require significant capital outlays, which we have no commitments for at this time. Finally, we will be restricted as to the kinds and types of advertising representations and claims that we make for certain applications.
We do not use and we anticipate that we will not utilize, manufacture or operate with substances deemed controlled under the Controlled Substances Act, administered by the Drug Enforcement Agency, or DEA, and therefore, no special procedures need be in place.
Because we do not actually do any material amount of testing, but rather, the manufacturing of devices that will be used as “tools”, we do not employ Centers for Disease Control/National Institutes of Health, Guidelines for Research Involving Recombinant DNA Molecules, Biosafety in Microbiological and Biomedical Laboratories, but, if and as our operations expand, may be required to do so in the future.
BIZM has no legal proceedings as shown as evidence in its 10K just filed with the SEC.gov and they did NOT sell Rule 144 stock (see below):
Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
As of May 21, 2013, we relocated our headquarters and principal executive offices to Wilhelmshoeher Allee 273A, Kassel, Germany, 34131, and our new phone number is 800-882-1683. Those offices, consisting of 1,722 square feet, are subleased to us by a related party, Opsolution GmbH, with an initial term of one year expiring on April 3, 2013 (and thereafter month-to-month), unless terminated with 60 days advance notice by either party to the other prior to such time.
Item 3. Legal Proceedings
There are no pending legal proceedings to which we are a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of our voting securities, or security holder is a party adverse to the Company or has a material interest adverse to us. Our property is not the subject of any pending legal proceedings.
However, on June 25, 2013, the SEC announced the suspension, pursuant to Section 12(k) of the Exchange Act, of trading in the securities of the Company, commencing at 9:30 a.m. EDT on June 25, 2013, and terminating at 11:59 p.m. EDT on July 9, 2013. The Commission suspended trading in the securities of the Company “due to a lack of current and accurate information concerning the securities of Biozoom because of concern that [sic] certain Biozoom affiliates and shareholders may have unjustifiably relied upon Rule 144 of the Securities Act of 1933 (‘Securities Act’) and they, Biozoom, and others may be engaged in an unlawful distribution of securities through the OTCBB.” Since the closing of the Opsolution Acquisition on February 28, 2013, to the best of the Company’s knowledge, none of the Company’s current officers and directors have sold Company securities through the OTCBB or relied upon Rule 144 or any other exemption from registration for resale of securities, and the Company’s attorneys have not issued any opinion letters regarding the resale of securities. The Company is currently investigating whether any other Company affiliates and shareholders have unjustifiably relied upon Rule 144 of the Securities Act.
Did the SEC/Government name BIZM? The answer is NO which means the SEC/Government obviously feel BIZM is NOT a scam. I rest my case. That is fact so we go on facts!
Buying/Hitting the Offer Hard in A.M. !!!!!!!!!
Stop misleading. No shares are being dumped. Look at the stock increasing 600% in a day and it will tell you right there that there is NO dilutions let alone Level II.
Plus that small increase in the O/S is meaningless and restricted shares being held by insiders. Heard the last conversion was well over a month ago and there are NO other conversions at ALL. There is a small note left that is being bought out from what I heard so no shares can be dumped which is evidence by the way the stock moves up and by level II.
I like Facts and the Facts are the SEC/Government says they are NOT a scam. Your opinion and others have opinions that this "could" be a scam but the SEC aka Government investigated BIZM and never named them so they are NOT a scam. BIZM has been proven innocent thus far and has NOT been named.
SEC/Government says BIZM is not a scam. So you are Wrong again and the Government has proven your opinion wrong because the Government aka the SEC did not name BIZM so its NOT a scam.
You are entitled to your opinion but the SEC aka Government is right because they are the regulators here and they did NOT find BIZM to be a scam and therefore they did NOT name BIZM.
Its the Law firm that's handling this imo and not BIZM because the law firm has plenty of experience. And yes I think they are very smart for working with the SEC and for doing this as I expect. Filing a new S-1 will get the uplisted in the next few months. Mark this post!
We already have the FACTS that BIZM and its counsel are working with the SEC. They are doing this to get the S-1 approved. Why would the SEC approve it? Because the SEC did NOT name BIZM they named the Argentinians and thats all the care about its not BIZM. So BIZM will get its new S-1 filed and approved soon imo.
BIZM Facts! Hmmm actually you're wrong there and the facts prove it. This stock was about 90% higher prior to the good ole Government coming in and killing it (halting it) and its innocent shareholders. Who will get the millions and millions that were ceased? Hmmmm the Government right? EXACTLY! The Government will likely keep all all the money it ceased and will not give it back to the "rightful" owners which would be the shareholders in my opinion. As usual the Government is likely to keep the money (just like they doing with FNMA) lol what a joke!
Enough said I go back to the facts and prior to the halt it was 90% higher and who halted it? The SEC. Thanks SEC for everything lol.
Stop misleading. Your post is wrong for a fact. The company was never named, the company never had "its" assets frozen and the company did not sell stock it was the Argentinians! The company was simply taken advantage of and thats why the SEC is letting it trade and the SEC did NOT name the company. Those are the facts by what the Government has released, thank you very much.
The U.S. Securities and Exchange Commission sued 10 Argentine citizens, claiming they illegally sold millions of shares of Biozoom Inc. (BIZM), a company that in April shifted its business from leather bags to biomedical technology.
Great post PMCM #2 Most Tweeted!
MUST READ PMCM LONGS - CEO of PMCM is Executive Producer for some of the Biggest Names in the Industry. DMX (Beast artist), Twista (ridiculous skills), Nate Dogg (1 of biggest of all times), Proof (Eminem's partner & best friend), Raheem (Huge and well known), 12 Gauge (Big star) and many more.
http://www.allmusic.com/artist/david-michery-mn0002153956
MUST READ LONGS - CEO of PMCM is Executive Producer for some of the Biggest Names in the Industry. DMX (Beast artist), Twista (ridiculous skills), Nate Dogg (1 of biggest of all times), Proof (Eminem's partner & best friend), Raheem (Huge and well known), 12 Gauge (Big star) and many more.
http://www.allmusic.com/artist/david-michery-mn0002153956
PMCM Acquiring Companies + $20MM in Revenue. PMCM news from last week plus the news thats coming this Tuesday as well as the huge news they have been releasing such as the acquisition and funding of Music Production and Record Company Top Sail Productions is huge!
PMCM Acquiring Companies + $20MM in Revenue. PMCM news from last week plus the news thats coming this Tuesday as well as the huge news they have been releasing such as the acquisition and funding of Music Production and Record Company Top Sail Productions is huge!
PMCM - Big News Mueziq Entertainment & PMCM in bed together. Just look at the bottom right of Mueziq Entertainment website and you will see PMCM http://mueziq.com/
Mueziq Entertainment - Founded in Atlanta, Ga. By Antwone Payne, Mueziq Entertainment, LLC. and Jewelry Box Publishing is An American Record Label, Media Group, and Ascap Publishing Company established in January, 2010, and is home to a diverse and unparalleled family of artists – from today’s icons to tomorrow’s Superstars. Mueziq Entertainment will be recognized as one of the most successful labels in the industry with distribution provided by the powerhouse ESMG.
Headed by Business Mogul Antwone Payne, A consummate music business professional, Payne’s allegiance to his Label Partners and artists are second to none, and he has achieved his goals in grand style from working with Platinum selling recording artist and producers, to developing his Industry acumen from legends in the game, such as David Michery, Jimmy Gates of the R & B group Silk, & Eddie Levert Jr. to name a few.
Big News Mueziq Entertainment & PMCM in bed together. Just look at the bottom right of Mueziq Entertainment website and you will see PMCM http://mueziq.com/
Mueziq Entertainment - Founded in Atlanta, Ga. By Antwone Payne, Mueziq Entertainment, LLC. and Jewelry Box Publishing is An American Record Label, Media Group, and Ascap Publishing Company established in January, 2010, and is home to a diverse and unparalleled family of artists – from today’s icons to tomorrow’s Superstars. Mueziq Entertainment will be recognized as one of the most successful labels in the industry with distribution provided by the powerhouse ESMG.
Headed by Business Mogul Antwone Payne, A consummate music business professional, Payne’s allegiance to his Label Partners and artists are second to none, and he has achieved his goals in grand style from working with Platinum selling recording artist and producers, to developing his Industry acumen from legends in the game, such as David Michery, Jimmy Gates of the R & B group Silk, & Eddie Levert Jr. to name a few.
PMCM hottest stock/easy 10 bagger.
PMCM Monster News coming Tuesday so Hold tight longs we can see nickel land this week easily!
PMCM NEWS: ES Music, the Music Label Division of Primco Management Inc., Announces the Commencement of Promotion and the U.S. Commercial Release Date for the V.I.C. Single "Turn Up"
June 5, 2013: Los Angeles, CA - Primco Management Inc. (OTCQB: PMCM) a fully integrated multi-media entertainment company today announced that, on the heels of its May 16, 2013 press release (which announced its groundbreaking music production, promotion and distribution partnership deal with Joe Isgro's and David Esterson's Phoenix 51) the ES Music Label will release the highly anticipated hit single "Turn Up" by double platinum recording artist V.I.C. on July 16, 2013. This will be the first single under the Primco/Phoenix 51 umbrella as well as the first release through Primco's newly established Top Sail/WEA distribution structure and relationship with the Warner Music Group. "Turn Up" was produced by Mr. Collipark and it follows the double platinum hit single "Wobble" which was also produced under the V.I.C and Mr. Collipark collaboration.
PMCM hottest stock/easy 10 bagger.
PMCM Monster News coming Tuesday so Hold tight longs we can see nickel land this week easily!
PMCM NEWS: ES Music, the Music Label Division of Primco Management Inc., Announces the Commencement of Promotion and the U.S. Commercial Release Date for the V.I.C. Single "Turn Up"
June 5, 2013: Los Angeles, CA - Primco Management Inc. (OTCQB: PMCM) a fully integrated multi-media entertainment company today announced that, on the heels of its May 16, 2013 press release (which announced its groundbreaking music production, promotion and distribution partnership deal with Joe Isgro's and David Esterson's Phoenix 51) the ES Music Label will release the highly anticipated hit single "Turn Up" by double platinum recording artist V.I.C. on July 16, 2013. This will be the first single under the Primco/Phoenix 51 umbrella as well as the first release through Primco's newly established Top Sail/WEA distribution structure and relationship with the Warner Music Group. "Turn Up" was produced by Mr. Collipark and it follows the double platinum hit single "Wobble" which was also produced under the V.I.C and Mr. Collipark collaboration.
PMCM could run to .12 cents you're right! PMCM has huge news this week on Tuesday with the release of the platinum artist single dropping.
PMCM could run to .12 cents you're right! PMCM has huge news this week on Tuesday with the release of the platinum artist single dropping.
PMCM was trading at .25 CENTS on 2/6/2013 so this stock can go many times higher from here. I'm looking for minimum a nickel this week and a dime by next week. This is based off a lot of upcoming news that's coming, a small float, management and key players.
PMCM was trading at .25 CENTS on 2/6/2013 so this stock can go many times higher from here. I'm looking for minimum a nickel this week and a dime by next week. This is based off a lot of upcoming news that's coming, a small float, management and key players.
PMCM CEO Produced this and this kid has some serious skills.
Executive Producer -- David Michery
Executive Producer [Co] -- J.M.
Management -- Linda Magee
Producer -- G-Mo
Programmed By, Engineer -- G-Mo
Written-By -- G-Mo
BIZM to file S-1 to be fully reporting again. There you go. I let the rabbit out of the hat as promised. As I mentioned I felt the company had a trick up their sleeve in order to skip all the b/s with the 15c211, Finra and market makers. All they have to do is refile (submit) their S-1 to up-list and become fully reporting again. This is exactly why the company filed its 10K just 2 weeks ago so they would be fully reporting and would NOT lose that status they needed when filing their new S-1.
We already have proof in the 10K and now in an email from the company that they are working with the SEC and their counsel to get things back on track and resolved which means their S-1 approved. BIZM would run wild once they update the market on this and or get it approved.
BIZM is and will be Up-listing again. They have a trick up their sleeve and I'm guessing they're doing exactly what I would do if I were in their shoes. Plus their email to me and several others here indicate they are taking the right approach in up-listing and working with the SEC and their counsel to get it approved.
It's called refilling your S-1. There you go board the rabbits out of the hat and guess what? They will uplist without all the headaches of the 15c211, market maker and Finra crap.
S-1 puts them right back to fully reporting just like they were prior to getting the wind knocked out of their sails.
Heard PMCM is already making money and it will show on the next Q. Also heard they have some big things kicking in soon that will add BIG numbers to the following Q. Holding tight here this one is going to nickel land this week and higher short term. By far this is the next NTEK type run from subbie to .15 cents.
Great BIZM Post, Research and DD. Its a pleasure to have you and your knowledge in this filed on the BIZM board. Appreciate all your professional knowledge you are bringing to the board here.
Technologies using Ramen spectoscropy, or compensation for temperature drift from LED's. The latter being a critical issue for target sampling in optiaics. It blows my mind that the company has 100% interest in the patent for a mathematical formula that corrects for this phenomenon.
And this is just one of the 19 patents Biozoom holds as a bonafide intellectual monetizable asset.
PMCM Monster Run Monday and Tuesday with Huge news so anyone selling or flipping will be missing on the Round 2 run coming here. I'm sure you'd agree with PMCM and their artist dropping the huge single on Tuesday the anticipation should build all week don't you agree?
Plus this is the partnership with PMCM and Warner Music Group which is frigging huge!
"Primco's newly established Top Sail/WEA distribution structure and relationship with the Warner Music Group.
PMCM is wayyyyyyyyyyyyyyy bigger and the CEO is fully connected and well respected in the music industry. This guy is a legend and PMCM is going to the moon based on his connections and relationships as well as the CFO because he (Alan Bailey) served as a Senior Financial Executive for Paramount Pictures, both in the Netherlands (their International head office), New York and Hollywood, California, including being its Senior Vice President & Treasurer.
Prior to joining Paramount Pictures, Alan was Vice President of Gulf & Western Industries in Bermuda, handling their offshore financial operations. Alan is an alumni of Ernst & Young and Grant Thornton ( CPA firms).
PMCM CEO previously served as President of Death Row Records (1999-2001), where he worked on releasing records of hip hop superstars such as, Tupac's Greatest Hits, which includes the #1 hit single; "Changes", Snoop Dogg's The Dog Pound, The Movie "Deathrow Uncut" and Deathrow's; "Chronic 2000."
CEO of PMCM is Connected Huge so that means PMCM can can biggie style since Big names are involved and the share structure is small.
PMCM to Hit .03 Fast! Breakout at .035 coming very soon which will send it sky high imo.
Looking to ADD HEAVY on the Open Monday for Round 2. Offer smacking coming up!
PMCM board marks at New high.